The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

IL2RB  -  interleukin 2 receptor, beta

Homo sapiens

Synonyms: CD122, High affinity IL-2 receptor subunit beta, IL-2 receptor subunit beta, IL-2R subunit beta, IL-2RB, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of IL2RB


Psychiatry related information on IL2RB


High impact information on IL2RB

  • Cells expressing a noncleavable mutant of p75 sustain DeltaPsim and ATP levels during apoptosis, and ROS production in response to apoptotic stimuli is dampened [8].
  • While cytochrome c release and DNA fragmentation are unaffected by the noncleavable p75 mutant, mitochondrial morphology of dying cells is maintained, and loss of plasma membrane integrity is delayed [8].
  • Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain [8].
  • Many investigations indicate that the survival-promoting signals of neurotrophins are generated by activation of Trk tyrosine kinase receptors and that their death-promoting signals are generated by activation of p75 neurotrophin receptors (p75(NTR)) [9].
  • Our results indicate that almost all T cells (greater than 98%) express neither the high affinity IL-2 receptor nor the functional intermediate affinity p75 chain of the IL-2 receptor without prior activation [10].

Chemical compound and disease context of IL2RB

  • MATERIAL/METHODS: The plasma levels of TNFalpha, its soluble receptor p75 (sTNF-RII), IL-6, and the soluble IL-6 receptor (sIL-6R) were measured using ELISA in 17 patients with ANCA-positive renal vasculitis (12 active - ANCA-A, 7 in remission ANCA-R), 9 patients with active lupus nephritis (LN), and 5 healthy subjects [11].
  • Recently, the genetic defect responsible for X-linked SCID has been identified as a mutation in the gamma chain of the IL-2 receptor, a protein also shared by the IL-4 and IL-7 receptors and therefore now denoted the common gamma chain (gamma c) [12].
  • Penta-acetyl geniposide induce apoptosis in C6 glioma cells by modulating the activation of neutral sphingomyelinase-induced p75 nerve growth factor receptor and protein kinase Cdelta pathway [13].
  • Exposure of SN56 cholinergic neuroblastoma cells to dibutyryl cAMP and retinoic acid for 3 days caused their morphologic differentiation along with the increase in choline acetyltransferase activity, acetylcholine content and release, calcium content, and the expression of p75 neurotrophin receptors [14].
  • Two borderline abnormal sweat chloride tests together with isolation of Pseudomonas from the airway caused clinicians initially to suspect CF; however, mutation in gene coding for the gamma-chain of the IL-2 receptor and a negative CF genetic mutation analysis ultimately led to the final diagnosis of SCID [15].

Biological context of IL2RB

  • Linkage between seven markers spanning chromosome 22 spaced approximately 10 cM apart (D22S264, D22S274, D22S301, D22S304, D22S421, IL2RB, and PDGFB) and VO2max at baseline, as well as its response to endurance exercise training, was examined using the sib-pair linkage method [16].
  • Patients with cancers of a histology previously reported to express the p55 component of the IL-2 receptor and who could not receive potentially more effective therapy were eligible for enrollment [17].
  • The role of IL-2 interaction with p75 and p55 receptor molecules in the stimulation of cell proliferation [18].
  • Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction [19].
  • In the present study, using the pre-B cell line Baf-B03 transfected with a truncated form of the IL-2 receptor (IL-2R) beta chain, we demonstrate that IL-2-dependent cell survival requires only the N-terminal 350 amino acids of the IL-2Rbeta chain [20].

Anatomical context of IL2RB

  • Cell lines bearing either the p55 Tac or the p75 peptide alone manifested low-affinity IL-2 binding, whereas a cell line bearing both peptides manifested both high- and low-affinity receptors [21].
  • Furthermore, fusion of cell membranes from low-affinity IL-2 binding cell lines bearing the Tac peptide alone with membranes from a cell line bearing the p75 peptide alone generated hybrid membranes bearing high-affinity receptors [21].
  • In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, bexarotene, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox [22].
  • This was in contrast to the partial inhibition of proliferation by anti-p75 or anti-TAC observed in unstimulated pretherapy peripheral blood lymphocytes suggesting that these cells respond to IL-2 through both high affinity receptors and intermediate affinity p75 receptors [23].
  • In this study, we present data indicating that NK cells activated by in vivo IL-2 treatment, in contrast to resting NK cells, respond and proliferate to further IL-2 in vitro using primarily the p75 receptor with only a minor component of cells responding through the high affinity receptor [23].

Associations of IL2RB with chemical compounds

  • The effect of DM on expression of IL-2R alpha (Tac, p55, CD25) and beta (p75) genes in activated T cells was examined next [24].
  • Lipopolysaccharide (LPS) upregulates expression of p75 and effectively induces surface expression of CD25 on human monocytes within 18 h, as detected by two-colour FACS analysis on 59.5 +/- 7.6% of cells [25].
  • Incubation of CD19+ cells with 10 ng/mL of TNF increased the incorporation of thymidine in 11 patients tested, and this was decreased to 65% (P < .05) by antibodies to the p55 receptor or the p75 receptor, and to 35% +/- 7% (P < .001) when both antibodies were combined [26].
  • Nevertheless, IL-2 stimulates the activation of one or more tyrosine kinases requiring the functional participation of the p75 member of the receptor complex [27].
  • Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A [28].

Physical interactions of IL2RB


Regulatory relationships of IL2RB

  • However, the p75 IL-2 receptor was expressed significantly in the IL-2-responsive monoclonal B-cell population [31].
  • In healthy controls, 0% to 1% of the CD19+ cells expressed the p55 receptor and 0% to 10% expressed the p75 receptor [26].
  • IL-18 up-regulated IL-2 receptor expression in mucosal lymphocytes from patients with CD, but not from normal controls [32].

Other interactions of IL2RB


Analytical, diagnostic and therapeutic context of IL2RB


  1. Human eosinophils express functional interleukin 2 receptors. Rand, T.H., Silberstein, D.S., Kornfeld, H., Weller, P.F. J. Clin. Invest. (1991) [Pubmed]
  2. Phenotypic analysis of hairy cell leukemia: "variant" cases express the interleukin-2 receptor beta chain, but not the alpha chain (CD25). de Totero, D., Tazzari, P.L., Lauria, F., Raspadori, D., di Celle, P.F., Carbone, A., Gobbi, M., Foa, R. Blood (1993) [Pubmed]
  3. Interleukin-4 bypass of the immunosuppressive effect mediated by interleukin-2 receptor antibodies. Steinmann, J., Herwartz, C., Müller-Ruchholtz, W. Scand. J. Immunol. (1993) [Pubmed]
  4. Expression of IL-2 receptor/p75 on lymphocytes from patients with rubella. Komada, Y., Oitani, K., Zhou, Y.W., Zhang, S.L., Sakurai, M. Acta paediatrica Japonica; Overseas edition. (1992) [Pubmed]
  5. The expression of the p75 subunit of interleukin 2 receptor in Tac negative leukemic cells of two patients with large granular lymphocytic leukemia. Tagawa, S., Hatakeyama, M., Shibano, M., Taniguchi, T., Kitani, T. Blood (1988) [Pubmed]
  6. Idiotypic immunoglobulin secretion by human B cell non-Hodgkin's lymphomas is related to the expression of the interleukin-2 receptor. Vyth-Dreese, F.A., Dellemijn, T.A., Hekman, A., Melief, C.J. Leukemia (1988) [Pubmed]
  7. Does the p75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer's disease? Coulson, E.J. J. Neurochem. (2006) [Pubmed]
  8. Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Ricci, J.E., Muñoz-Pinedo, C., Fitzgerald, P., Bailly-Maitre, B., Perkins, G.A., Yadava, N., Scheffler, I.E., Ellisman, M.H., Green, D.R. Cell (2004) [Pubmed]
  9. The protean actions of neurotrophins and their receptors on the life and death of neurons. Kalb, R. Trends Neurosci. (2005) [Pubmed]
  10. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. Caligiuri, M.A., Zmuidzinas, A., Manley, T.J., Levine, H., Smith, K.A., Ritz, J. J. Exp. Med. (1990) [Pubmed]
  11. Soluble cytokine receptors in renal vasculitis and lupus nephritis. Tesar, V., Jirsa, M., Zima, T., Kalousová, M., Bartunková, J., Stejskalová, A., Dostál, C., Zabka, J. Med. Sci. Monit. (2002) [Pubmed]
  12. Retroviral vector for gene therapy of X-linked severe combined immunodeficiency syndrome. Qazilbash, M.H., Walsh, C.E., Russell, S.M., Noguchi, M., Mann, M.M., Leonard, W.J., Liu, J.M. Journal of hematotherapy. (1995) [Pubmed]
  13. Penta-acetyl geniposide induce apoptosis in C6 glioma cells by modulating the activation of neutral sphingomyelinase-induced p75 nerve growth factor receptor and protein kinase Cdelta pathway. Peng, C.H., Huang, C.N., Hsu, S.P., Wang, C.J. Mol. Pharmacol. (2006) [Pubmed]
  14. Phenotype-dependent susceptibility of cholinergic neuroblastoma cells to neurotoxic inputs. Szutowicz, A., Bielarczyk, H., Gul, S., Ronowska, A., Pawe??czyk, T., Jankowska-Kulawy, A. Metabolic brain disease (2006) [Pubmed]
  15. A 5-month-old boy with recurrent respiratory infections, failure to thrive, and borderline elevated sweat chloride levels. Wang, H.C., Whelan, M.A., McGeady, S.J., Yousef, E. Allergy and asthma proceedings : the official journal of regional and state allergy societies. (2006) [Pubmed]
  16. Absence of linkage between VO2max and its response to training with markers spanning chromosome 22. Gagnon, J., Ho-Kim, M.A., Chagnon, Y.C., Pérusse, L., Dionne, T., Leon, A.S., Rao, D.C., Skinner, J.S., Wilmore, J.H., Bouchard, C. Medicine and science in sports and exercise. (1997) [Pubmed]
  17. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. LeMaistre, C.F., Craig, F.E., Meneghetti, C., McMullin, B., Parker, K., Reuben, J., Boldt, D.H., Rosenblum, M., Woodworth, T. Cancer Res. (1993) [Pubmed]
  18. The role of IL-2 interaction with p75 and p55 receptor molecules in the stimulation of cell proliferation. Perkins, G.R., Flemming, C.L., Kabat, D., Collins, M.K. Int. Immunol. (1993) [Pubmed]
  19. Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. Ortaldo, J.R., Mason, A.T., O'Shea, J.J., Smyth, M.J., Falk, L.A., Kennedy, I.C., Longo, D.L., Ruscetti, F.W. J. Immunol. (1991) [Pubmed]
  20. An IL-2 receptor beta subdomain that controls Bcl-X(L) expression and cell survival. Ciprés, A., Gala, S., Martinez-A, C., Mérida, I., Williamson, P. Eur. J. Immunol. (1999) [Pubmed]
  21. Contribution of a p75 interleukin 2 binding peptide to a high-affinity interleukin 2 receptor complex. Tsudo, M., Kozak, R.W., Goldman, C.K., Waldmann, T.A. Proc. Natl. Acad. Sci. U.S.A. (1987) [Pubmed]
  22. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Foss, F., Demierre, M.F., DiVenuti, G. Blood (2005) [Pubmed]
  23. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Weil-Hillman, G., Voss, S.D., Fisch, P., Schell, K., Hank, J.A., Sosman, J.A., Sugamura, K., Sondel, P.M. Cancer Res. (1990) [Pubmed]
  24. Glucocorticoid-mediated inhibition of interleukin-2 receptor alpha and -beta subunit expression by human T cells. Batuman, O.A., Ferrero, A.P., Diaz, A., Berger, B., Pomerantz, R.J. Immunopharmacology (1994) [Pubmed]
  25. The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75). Scheibenbogen, C., Keilholz, U., Richter, M., Andreesen, R., Hunstein, W. Res. Immunol. (1992) [Pubmed]
  26. p55 and p75 tumor necrosis factor receptors in patients with chronic lymphocytic leukemia. Waage, A., Liabakk, N., Lien, E., Lamvik, J., Espevik, T. Blood (1992) [Pubmed]
  27. Characterization of a tyrosine kinase activity associated with the high-affinity interleukin 2 receptor complex. Garcia, G.G., Evans, G.A., Michiel, D.F., Farrar, W.L. Biochem. J. (1992) [Pubmed]
  28. Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A. Foxwell, B.M., Simon, J., Herrero, J.J., Taylor, D., Woerly, G., Cantrell, D., Ryffel, B. Immunology (1990) [Pubmed]
  29. The role of the multichain IL-2 receptor complex in the control of normal and malignant T-cell proliferation. Waldmann, T.A. Environ. Health Perspect. (1987) [Pubmed]
  30. A second sequence element located 3' to the NF-kappa B-binding site regulates IL-2 receptor-alpha gene induction. Pomerantz, J.L., Mauxion, F., Yoshida, M., Greene, W.C., Sen, R. J. Immunol. (1989) [Pubmed]
  31. Interleukin-2-induced increase of a monoclonal B-cell lymphocytosis. A novel in vivo interleukin-2 effect? Tiberghien, P., Racadot, E., Deschaseaux, M.L., Delain, M., Voillat, L., Billot, M., Flesch, M., Rozenbaum, A., Brandely, M., Cahn, J.Y. Cancer (1992) [Pubmed]
  32. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease. Kanai, T., Watanabe, M., Okazawa, A., Nakamaru, K., Okamoto, M., Naganuma, M., Ishii, H., Ikeda, M., Kurimoto, M., Hibi, T. Gastroenterology (2000) [Pubmed]
  33. Expression on cells of early human pregnancy decidua, of the p75, IL-2 and p145, IL-4 receptor proteins. Starkey, P.M. Immunology (1991) [Pubmed]
  34. TNF receptor distribution in human tissues. Ryffel, B., Mihatsch, M.J. International review of experimental pathology. (1993) [Pubmed]
  35. The Trypanosoma cruzi membrane glycoprotein AGC10 inhibits human lymphocyte activation by a mechanism preceding translation of both, interleukin-2 and its high-affinity receptor subunits. Kierszenbaum, F., Fresno, M., Sztein, M.B. Mol. Biochem. Parasitol. (2002) [Pubmed]
  36. Molecular regulation of hematopoietic cytokines: implications and indications for clinical use in pediatric oncology. Burdach, S. Medical and pediatric oncology. Supplement. (1992) [Pubmed]
  37. Expression of p75 chain of IL-2 receptor in the early immunological reconstitution after allogeneic bone marrow transplantation. Comoli, P., Maccario, R., Montagna, D., Labirio, M., Zecca, M., Clementi, R., Bonetti, F., Locatelli, F. Clin. Exp. Immunol. (1994) [Pubmed]
  38. Expression of IL-2 receptor p55 and p75 chains by human B lymphocytes: effects of activation and differentiation. Zola, H., Weedon, H., Thompson, G.R., Fung, M.C., Ingley, E., Hapel, A.J. Immunology (1991) [Pubmed]
  39. Mobilizable intracellular pool of p55 (type I) tumor necrosis factor receptors in human neutrophils. Porteu, F., Nathan, C.F. J. Leukoc. Biol. (1992) [Pubmed]
  40. IL-2 receptor subunit, p75: direct demonstration of its IL-2 binding ability by using a novel monoclonal antibody. Suzuki, J., Takeshita, T., Ohbo, K., Asao, H., Tada, K., Sugamura, K. Int. Immunol. (1989) [Pubmed]
WikiGenes - Universities